Vnitr Lek 2023, 69(4):265-268 | DOI: 10.36290/vnl.2023.050

Initial use of subcutaneous plasma-derived C1 inhibitor in prophylaxis of acute attacks of hereditary angioedema in pregnant patients in Slovakia

Katarína Hrubišková1, Miloš Jeseňák2, 3, Juraj Payer1
1 Centrum pre hereditárny angioedém - Expertízne pracovisko MZ SR pre zriedkavé choroby, V. interná klinika Lekárskej fakulty Univerzity Komenského a Univerzitnej nemocnice Bratislava
2 Centrum pre hereditárny angioedém - Expertízne pracovisko MZ SR pre zriedkavé choroby, Klinika detí a dorastu, Klinika pneumológie a ftizeológie, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Univerzitná nemocnica Martin
3 Oddelenie klinickej imunológie a alergológie, Univerzitná nemocnica Martin

Hereditary angioedema (HAE) is a rare, inborn disease manifested with recurrent attacks of angioedema. They can affect the skin and subcutaneous tissue, mucous membranes (gastrointestinal, respiratory, and uropoietic tracts), and submucous tissue. Women in reproductive age require specific management of the disease regarding both the course of the disease and treatment options. It is not only the treatment in female patients that is specific, but also the situations (pregnancy, breastfeeding). We present a case report of the initial use of a subcutaneous C1 inhibitor in the long-term prophylaxis of HAE attacks in two pregnant patients.

Keywords: hereditary angioedema, prophylaxis, pregnancy.

Accepted: May 31, 2023; Published: June 22, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrubišková K, Jeseňák M, Payer J. Initial use of subcutaneous plasma-derived C1 inhibitor in prophylaxis of acute attacks of hereditary angioedema in pregnant patients in Slovakia. Vnitr Lek. 2023;69(4):265-268. doi: 10.36290/vnl.2023.050.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Davis AE 3rd, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol. 2008 Oct;45(16):4057-63. doi: 10.1016/j.molimm.2008. 06. 028. Epub 2008 Jul 31. PMID: 18674818; PMCID: PMC2626406. Go to original source... Go to PubMed...
    2. Maurer M, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy, 2022;77(7): 1961-1990. https://doi.org/10.1111/all.15214. Go to original source... Go to PubMed...
    3. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. AnnIntern Med. 1976;84:580-593. Go to original source... Go to PubMed...
    4. Agostoni A, Aygören­‑Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J AllergyClinImmunol. 2004;114(suppl 3):S51-S131. doi: 10.1016/j.jaci.2004. 06. 047. Go to original source...
    5. Valerieva A, Staevska MT, Grivcheva­‑Panovska V, et al. Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry. WorldAllergy Organ J. 2021 Apr 22;14(4):100535. doi: 10.1016/j.waojou.2021.100535. PMID: 33995818; PMCID: PMC8093463 Go to original source... Go to PubMed...
    6. Joseph K, Tholanikunnel BG, Kaplan AP. Cytokine and estrogen stimulation of endothelial cells augments activation of the prekalikrein­‑high molecular weight kininogen complex. Implications for hereditary angioedema. J AllergyClinImmunol. 2017;140(1):170-6. Go to original source...
    7. Bork K, Men G, StaubachP, Hardt. Hereditary angioedema: new findings concerning symptomas, affected organs, and course. Am J Med.2006;119:267-74. Go to original source...
    8. Banerji A, Riedl M. Managing the female patient with hereditary angiedema, WomensHealth (lond). 2016;12:351-61. Go to original source... Go to PubMed...
    9. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J AllergyclinImmunol. 2012;129(2):308-20. Go to original source... Go to PubMed...
    10. Hakl R, Kuklínek P, Krčmová I, et al. Treatment of hereditary angioedema attacks with icatibant and recombinant C1 inhibitor during pregnancy. J ClinImmunol. 2018;38(7):810-5. Go to original source... Go to PubMed...
    11. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA MedicalAdvisoryBoard 2020 Guidelines for the Management of Hereditary Angioedema. J AllergyClinImmunolPract. 2021;9(1):132-150e3. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.